LFCR at a glance
LIFECORE BIOMEDICAL, INC. DE (LFCR, SEC CIK 1005286) filed its latest 10-K annual report on August 7, 2025, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as June 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended May 25, 2025 (FY2025), LIFECORE BIOMEDICAL, INC. DE (LFCR) reported revenue of $128.9 million (up 0.5% from FY2024) and a net loss of $38.7 million. Diluted EPS was -$1.27.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding LIFECORE BIOMEDICAL, INC. DE (LFCR) shares worth $31.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $128.9M
- +0.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $31.0M · +2 vs prior quarter
- Latest 8-K
- Sep 29, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $34.167M, down 6% YoY from $36.444M
- Gross margin 35.3% vs 38.4% YoY
- HA manufacturing best performer: revenue $18.615M, up 44%; CDMO worst: $15.552M, down 34%
- Cash $17.2M plus $21.6M borrowing availability; no revolving debt outstanding
- Outlook: over 40 cost-reduction projects; headwinds include rising Alcon loan interest and customer project timing
Risk Factors
- No new regulatory, legal, compliance, operational, competitive, market, or financial risks identified
- No director or executive adopted or terminated trading arrangements during three months ended June 30, 2026
AI summary of the LFCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Alcon manufacturing agreement extended from December 31, 2031 to December 31, 2034
- Automatic 24-month renewals after 2034, subject to termination notice
Item 7.01: Regulation FD Disclosure
- Exhibits 99.3 and 99.4 excluded from Securities Act incorporation by reference
- No substantive Regulation FD disclosure included in the provided text
Item 1.01: Entry into a Material Definitive Agreement
- Webster affiliates to acquire Lifecore for $6.28 cash per common share plus one non-tradeable CVR
- CVRs could pay $30M in 2028, $45M in 2029, and $85M in 2030, contingent on revenue and EBITDA milestones
Item EX-99.1: Item EX-99.1
- Webster Equity Partners acquisition offers $6.28 per common share, a 49.5% premium to September 25, 2026’s closing price
- CVRs could add up to $160 million, raising potential consideration to $9.67 per common equivalent
Item 2.02: Results of Operations and Financial Condition
- Q2 and six-month financial results ended June 30, 2026 announced August 5, 2026
- Detailed results and management commentary available in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Investor presentation furnished under Reg FD, providing market-facing information to investors
- Exhibit 99.2 contains the substantive presentation materials and likely details management’s current messaging
Item EX-99.1: Item EX-99.1
- Q2 2026 revenue $34.2M, net loss $(6.2)M, and Adjusted EBITDA $8.6M
- 2026 guidance reaffirmed: revenue $120-$125M and Adjusted EBITDA $20.5-$25M
AI summaries of LFCR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LFCR
Don't miss the next LFCR filing
- Alerts as it files. A push when LFCR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LFCR, by share count.
- Ask anything. An AI agent that reads every LFCR filing and answers with sources.
LFCR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| OBUS NELSON | A | Jun 4, 2026 | 25,907 | - |
| Kiper Christopher S | A | Jun 4, 2026 | 25,907 | - |
| Antunes Humberto Calheiros | A | Jun 4, 2026 | 25,907 | - |
| Johnson Paul Harold | A | Jun 4, 2026 | 25,907 | - |
| Korenberg Matthew E | A | Jun 4, 2026 | 25,907 | - |
| Schechter Joshua | A | Jun 4, 2026 | 25,907 | - |
| HOUDE LOVAS KATRINA | A | Jun 4, 2026 | 25,907 | - |
| Aryeh Jason | A | Jun 4, 2026 | 25,907 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $128.3M | $128.9M |
| Gross Profit | - | $41.9M | $40.3M |
| Operating Income | - | -$8.8M | -$17.2M |
| Net Income | - | $12.0M | -$38.7M |
| Gross Margin | - | 32.6% | 31.3% |
| Op. Margin | - | -6.9% | -13.4% |
| Net Margin | - | 9.4% | -30.0% |
| Balance Sheet | |||
| Total Assets | $253.5M | $254.0M | $239.3M |
| Equity | - | $11.3M | $1.3M |
| ROE | - | 106.2% | -2898.0% |
| Per Share | |||
| EPS | $-3.32 | $0.32 | $-1.27 |
| Cash Flow | |||
| Operating CF | - | -$217K | -$206K |
| CapEx | - | $18.4M | $13.4M |
Source: XBRL data in LIFECORE BIOMEDICAL, INC. DE (LFCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LFCR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $31.0M |
| Q1 2026 | 19 | $20.4M |
| Q4 2025 | 21 | $47.6M |
| Q3 2025 | 19 | $39.7M |
| Q2 2025 | 20 | $46.2M |
| Q1 2025 | 15 | $23.1M |
| Q4 2024 | 10 | $20.7M |
| Q3 2024 | 6 | $2.9M |
- BlackRock+135.8K (+7%)
- AQR Capital Management+39.7K (+250%)
- State Street Corp+26.0K (+4%)
- Northern Trust+25.7K (+11%)
- Vanguard Portfolio Management LLC+24.5K (+15%)
- Goldman Sachs Group−43.4K (-26%)
- Millennium Management−23.9K (-15%)
- Bank of America Corp−6.1K (-14%)
- Vanguard Capital Management LLC−1.5K (-0%)
- Fifth Third Bancorp−69 (-33%)
- Renaissance Technologies LLC+104.9K
- Citadel Advisors LLC+98.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 131 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LFCR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 16, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| 4 | Mar 2, 2026 | - | - | - |
| SC 13G | Jan 21, 2026 | - | - | |
| 8-K | Jan 16, 2026 | - | - | |
| 10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LFCR SEC filings: frequently asked questions
Which institutions hold LFCR stock?
As of June 30, 2026, the largest LIFECORE BIOMEDICAL, INC. DE (LFCR) holders among the 13F filers tracked by SignalX were BlackRock ($10.6 million), Vanguard Capital Management LLC ($6.8 million), Morgan Stanley ($4.0 million), State Street Corp ($3.5 million), Northern Trust ($1.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LFCR's revenue in fiscal year 2025?
For the fiscal year ended May 25, 2025 (FY2025), LIFECORE BIOMEDICAL, INC. DE (LFCR) reported revenue of $128.9 million (up 0.5% from FY2024) and a net loss of $38.7 million. Diluted EPS was -$1.27. The figures come from the XBRL data in the 10-K.
What did LFCR report in its latest 8-K?
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K on September 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Alcon manufacturing agreement extended from December 31, 2031 to December 31, 2034.
What are the latest LFCR SEC filings?
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its latest 10-K annual report on August 7, 2025, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on June 8, 2026.
What is LFCR's SEC CIK number?
LIFECORE BIOMEDICAL, INC. DE (LFCR)'s SEC Central Index Key (CIK) is 1005286. EDGAR lists every LFCR filing under that number.
Ask anything about LFCR
The research agent reads LFCR's filings, financials, insider trades and 13F holders, then answers with sources.